GlobeNewsWire
29 Sept 2026, 12:45 UTC · 41m ago
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
Verdict
Headline takes no side. We score VVOS +0.80 across five claims — strongly bullish.
- Expected · VVOS
+0.80strongly bullish
−1 bearish0bullish +1More positive than 89% of ticker scores this week
- Actual





